FibroBiologics Inc. Faces Nasdaq Delisting Risk Due to Sub-$1 Share Price

Reuters
04 Jul
<a href="https://laohu8.com/S/FBLG">FibroBiologics</a> Inc. Faces Nasdaq Delisting Risk Due to Sub-$1 Share Price

FibroBiologics Inc. has received a notification from The Nasdaq Stock Market LLC indicating that the company has failed to meet the minimum closing bid price requirement of $1.00 per share for the past 30 consecutive trading days. Despite this, FibroBiologics' shares will continue to be listed on the Nasdaq Capital Market as long as the company complies with other listing requirements. The company now has until December 29, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If compliance is not achieved by this deadline, FibroBiologics may qualify for an additional 180-day compliance period, provided it meets other listing criteria. Failure to meet these conditions could result in the delisting of the company's securities, although FibroBiologics has the option to appeal such a decision.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-093832), on July 03, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10